Dutalys is a privately owned antibody technology company based in Vienna, Austria, and was established as a GmbH in April 2010. We are a small, growing and highly motivated team of people with diverse backgrounds, joined by a shared commitment to channel state-of-the-art empirical and computational approaches towards creating more effective antibody drugs.
We have developed the proprietary Dutabody™ platform technology, creating a novel class of fully human therapeutic antibody molecules, which are suitable for the treatment of disease mechanisms and therapeutic targets that are too complex for successful treatment with other more conventional antibodies. Following major scientific breakthroughs in the development of this platform technology we achieved proof-of-concept in 2010. In 2011 we successfully applied the technology to several potential therapeutic targets and are now committed to its commercialisation as well as the development of an exciting proprietary pipeline.